- Home
- NTLA vs NVGS Comparison
NTLA vs NVGS Comparison
Compare NTLA & NVGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- NVGS
- Stock Information
- Founded
- NTLA 2014
- NVGS 1997
- Country
- NTLA United States
- NVGS United Kingdom
- Employees
- NTLA N/A
- NVGS N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NVGS Marine Transportation
- Sector
- NTLA Health Care
- NVGS Consumer Discretionary
- Exchange
- NTLA Nasdaq
- NVGS Nasdaq
- Market Cap
- NTLA 1.2B
- NVGS 994.3M
- IPO Year
- NTLA 2016
- NVGS N/A
- Fundamental
- Price
- NTLA $12.06
- NVGS $16.63
- Analyst Decision
- NTLA Buy
- NVGS Strong Buy
- Analyst Count
- NTLA 20
- NVGS 2
- Target Price
- NTLA $32.30
- NVGS $21.50
- AVG Volume (30 Days)
- NTLA 4.2M
- NVGS 304.9K
- Earning Date
- NTLA 08-07-2025
- NVGS 11-05-2025
- Dividend Yield
- NTLA N/A
- NVGS 1.23%
- EPS Growth
- NTLA N/A
- NVGS 12.51
- EPS
- NTLA N/A
- NVGS 1.26
- Revenue
- NTLA $52,857,000.00
- NVGS $566,889,000.00
- Revenue This Year
- NTLA $8.32
- NVGS $2.20
- Revenue Next Year
- NTLA N/A
- NVGS N/A
- P/E Ratio
- NTLA N/A
- NVGS $12.94
- Revenue Growth
- NTLA 14.99
- NVGS 1.19
- 52 Week Low
- NTLA $5.90
- NVGS $10.55
- 52 Week High
- NTLA $23.76
- NVGS $17.53
- Technical
- Relative Strength Index (RSI)
- NTLA 60.10
- NVGS 62.56
- Support Level
- NTLA $11.29
- NVGS $15.88
- Resistance Level
- NTLA $12.46
- NVGS $16.27
- Average True Range (ATR)
- NTLA 0.56
- NVGS 0.33
- MACD
- NTLA 0.12
- NVGS 0.02
- Stochastic Oscillator
- NTLA 84.85
- NVGS 99.61
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.